GLG Pharma Corporation (GLG) is a private, clinical-stage biotechnology company delivering next-generation therapies for hyper-proliferative diseases. We are developing novel STAT3 pathway therapies we believe will forge a new generation of targeted treatments. The drugs we are developing target abnormal STAT3 pathway regulation, and we are focused on combining our STAT3 compounds with Standard-of-Care chemotherapeutics to provide targeted treatments. STAT3 is normally used during development where it mediates the expression of a variety of genes in response to cell stimuli, and plays a key role in many cellular processes such as cell survival, growth, division, pluripotency and apoptosis as well as immune system evasion. The rationale for focusing on STAT3 is that a large number of cancer types and subtypes, as well as refractory cancers of other types/subtypes, are driven by and dependent on STAT3 dysfunction.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
GLG-805 and GLG-305
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):